紫杉醇与卡铂同步联合放疗治疗原发性宫颈癌。
Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer.
作者信息
de Vos F Y F L, Bos A M E, Gietema J A, Pras E, Van der Zee A G J, de Vries E G E, Willemse P H B
机构信息
Department of Medical Oncology, Groningen University Hospital, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
出版信息
Anticancer Res. 2004 Jan-Feb;24(1):345-8.
BACKGROUND
Concurrent radiochemotherapy is currently considered the new standard treatment in locally advanced cervical cancer.
PATIENTS AND METHODS
Eight women with cervical cancer stage IB2-IVA were treated with standard radiation therapy in combination with standard carboplatin (AUC=2, once weekly, x 6) and escalating doses of paclitaxel (60 mg/m2, once weekly, x 4, then x 5 and x 6).
RESULTS
At the lowest dose level, four weekly paclitaxel cycles in six patients, three developed grade III diarrhoea and one severe radiation enteritis several weeks after radiotherapy. Two patients did not achieve complete remission and underwent additive salvage hysterectomy. All patients remained free of local recurrence, but one patient had distant metastases after 13 months. The median disease-free survival was 25 months with a median follow-up of 26 months.
CONCLUSION
Standard pelvic radiotherapy in combination with weekly carboplatin and paclitaxel is poorly tolerated due to dose-limiting diarrhoea.
背景
同步放化疗目前被认为是局部晚期宫颈癌的新标准治疗方法。
患者与方法
8例IB2-IVA期宫颈癌女性患者接受了标准放疗联合标准剂量卡铂（AUC = 2，每周一次，共6次）以及递增剂量紫杉醇（60mg/m²，每周一次，共4次，然后依次为5次和6次）的治疗。
结果
在最低剂量水平时，6例患者接受4周紫杉醇治疗周期，其中3例出现III级腹泻，1例在放疗数周后出现严重放射性肠炎。2例患者未实现完全缓解，随后接受了补救性子宫切除术。所有患者均无局部复发，但1例患者在13个月后出现远处转移。无病生存期的中位数为25个月，中位随访时间为26个月。
结论
由于剂量限制性腹泻，标准盆腔放疗联合每周一次卡铂和紫杉醇的耐受性较差。
Zotero 插件